Wyeth Articles
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
Wyeth appoints Daniel McIntyre as VP of corporate communications
8 September 2008
FDA labeling rule upsets trial lawyers
1 September 2008
Boehringer extends Ablynx AD accord
1 September 2008
Thomson releases Pharma Matters reports for 1st qtr
1 September 2008
Ligand reports second quarter in loss
1 September 2008
US FDA set for even fewer approvals in 2008
1 September 2008
NEJM editors side against Wyeth
1 September 2008
Drug majors protest FASB legal cost disclosure plan
18 August 2008
Retail drug sales in year to June 2008
18 August 2008
Law suits stall awaiting FDA pre-emption verdict
18 August 2008
Stock Commentary - Europe - week to Aug 4, 2008
11 August 2008
Stock Commentary - New York week to Aug 4, 2008
11 August 2008
UK cancer charity slams NICE methods
11 August 2008
Pharmacopeia receives milestone from Wyeth
11 August 2008
Strong Ph II data on Prana's PBT2
11 August 2008
Wyeth/Elan shares drop on discouraging side effect profile of AD drug in mid-stage study
4 August 2008
Retail drug sales in year to May 2008
4 August 2008
Retail drug sales in year to April 2008
28 July 2008
NICE rejects second-line use of TNF-alpha drugs
28 July 2008
Wyeth and Impax reach Effexor accord
28 July 2008
$27M damages thrown out for Wyeth/Upjohn
21 July 2008
EC clears higher dose of Wyeth
14 July 2008
ImClone completes Ph I trial enrollment
14 July 2008
Japan stock market week to July 7, 2008
14 July 2008
OrbusNeich claims bio-stent is superior
14 July 2008
Attempt in US Congress to stop FDA pre-emption
14 July 2008
Wyeth/Progenics' Reslitor approved in EU
14 July 2008
Trubion extends research partnership with Wyeth
7 July 2008
Myriad/Lundbeck drop Ph III AD drug Flurizan
7 July 2008
Stock Commentary - New York week to June 23, 2008
30 June 2008
Stock Commentary - Europe - week to June 23, 2008
30 June 2008
CORRECTION: Enbrel recommendation
30 June 2008
Singapore reinforces position as a global site for pharma and biotech; output quadruples
30 June 2008
Amgen/Wyeth receive OK from FDA for Enbrel
30 June 2008
Wyeth reports positive data from COMET trial
30 June 2008
FDA approves Mylan's generic Effexor
23 June 2008
Enbrel improves two measures of remission
23 June 2008
Retail drug sales in year to March 2008
16 June 2008
Ph III data for Wyeth's Relistor injection
9 June 2008
Wyeth's Tygacil gets FDA "appro" letter
9 June 2008
GVK partners with Wyeth
2 June 2008
FDA OKs Osmoteca's venlafaxine ER
2 June 2008
ArQule's 1st-qtr loss narrows to $13.9M
26 May 2008
PIP recommendations from EMEA's PDCO
26 May 2008
Crucell's 1st-qtr 2008 loss halves on sales
26 May 2008
Wyeth debuts Pristiq in US pharmacies
19 May 2008
Retail drug sales in year to February 2008
19 May 2008
Amgen reports nearly flat 1st qtr
5 May 2008
Lundbeck appoints Ulf Wiinberg as CEO
5 May 2008
FDA approves Wyeth & Progenics' Relistor
5 May 2008
Wyeth beats forecasts despite generics
5 May 2008
Wyeth chairman Essner to retire June 27
5 May 2008
Wyeth withdraws US CAP Tygacil application
5 May 2008
Retail drug sales in year to January 2008
21 April 2008
Mylan seeks more generic market share
7 April 2008
Wyeth milestone for ArQule on AD drug
31 March 2008
Locaserin trial passes 1-year safety review
31 March 2008
Boxed warnings for Amgen/Wyeth's Enbrel
24 March 2008
Wyeth halts Hedgehog agonist deal with Curis
17 March 2008
Crucell to manufacture parts of Wyeth vaccine
10 March 2008
Wyeth and Solvay end bifeprunox accord
10 March 2008
Wyeth's Pristiq cleared for adults with MDD
10 March 2008
Centocor's psoriasis drug accepted for FDA review
10 March 2008
Everolimus trial halted after early PFS gains
10 March 2008
SCOTUS signals FDA pre-emption support
3 March 2008
FDA approves Wyeth's hemophilia A drug
3 March 2008
SCOTUS signals support for FDA pre-emption
3 March 2008
Wyeth granted summary judgement in vaccines case
25 February 2008
US Defense Department switches to Acambis' small pox vacc
18 February 2008
Ustekinumab: "gold standard" for psoriasis by 2011
18 February 2008
Teva's 4th-qtr income climbs 24% US sales
18 February 2008
Karo Bio's 2007 loss up 63% on R&D costs
18 February 2008
Wyeth elects Timothy Cost as SVP of corporate affairs
11 February 2008
Wyeth's 4th-qtr 2007 income climbs 18% just shy of estimates; predicts flat 2008 on generic competition
11 February 2008
FDA advisors declare the agency's "science and mission are at risk"
11 February 2008
Pfizer announces Exubera job cuts; Wyeth may cut workforce 10%
4 February 2008
Lilly hits back at data suppression claims
28 January 2008
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
